Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Roituximab and Chemotherapy

Clinical Trial Grant

Duke Scholars

Principal Investigator Matthew Stuart McKinney Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Atara Biotherapeutics, Inc.

Start Date

January 6, 2020

End Date

January 17, 2025

Administered By

Duke Cancer Institute

Awarded By

Atara Biotherapeutics, Inc.

Start Date

January 6, 2020

End Date

January 17, 2025